Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0SHMMA
ADC Name
JP2025004232A ADC9
Synonyms
ADC9
   Click to Show/Hide
Organization
Sumitomo Pharma Co., Ltd
Drug Status
Investigative
Drug-to-Antibody Ratio
7.3
Structure
Antibody Name
Trastuzumab
  Antibody Info 
Antigen Name
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
  Antigen Info 
Payload Name
Undisclosed
Therapeutic Target
Stimulator of interferon genes protein (STING1)
  Target Info 
Linker Name
Undisclosed
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
Combination Type
M3
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal inhibitory Concentration (lC50) 
0.21
nM
CVCL_0033
Breast adenocarcinoma
Half Maximal inhibitory Concentration (lC50) 
3.77
nM
CVCL_1324
ALK-positive anaplastic large cell lymphoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
0.21 nM
Method Description
The SK-BR-3 cells (ATCC), which are negative for CD30 antigen but positive for HER2 antigen, were cultured to reach 2×106 cells/mL. 50 uL of each was added to 96-well cell culture microplates. 50 uL of CellTiter-Glo Luminescent Cell Viability Assay (Promega) was added to each well and mixed. The mixture was incubated in the dark for 20 minutes. The luminescence was measured using a microplate illuminometer, and the cell survival rates at each ADC concentration were calculated accordingly.The IC50 value can be calculated based on the value of cell survival rate.

   Click to Show/Hide
In Vitro Model Breast adenocarcinoma SK-BR-3 cells CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
3.77 nM
Method Description
The Karpas-299 cells (ECACC), which express CD30 antigen and are negative for HER2 antigen, were cultured to reach 2×106 cells/mL. 50 uL of each was added to 96-well cell culture microplates. 50 uL of CellTiter-Glo Luminescent Cell Viability Assay (Promega) was added to each well and mixed. The mixture was incubated in the dark for 20 minutes. The luminescence was measured using a microplate illuminometer, and the cell survival rates at each ADC concentration were calculated accordingly.The IC50 value can be calculated based on the value of cell survival rate.

   Click to Show/Hide
In Vitro Model ALK-positive anaplastic large cell lymphoma Karpas-299 cells CVCL_1324
References
Ref 1 Antibody-drug complexes containing hemiasterlin derivatives